ClinVar Miner

Submissions for variant NM_000371.3(TTR):c.417G>A (p.Thr139=) (rs2276382)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000248562 SCV000318727 likely benign Cardiovascular phenotype 2015-04-22 criteria provided, single submitter clinical testing
Athena Diagnostics Inc RCV000587633 SCV000844812 benign not provided 2018-08-13 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000587633 SCV000696634 benign not provided 2016-04-28 criteria provided, single submitter clinical testing Variant summary: The c.417G>A variant involves the alteration of a non-conserved nucleotide resulting in a synonymous change. 5/5 in silico tools via Alamut the gain of a cryptic splice acceptor site, however, the significance of these predictions has not been supported with functional studies. The variant was observed in the large and broad cohorts of the ExAC project at an allele frequency of 0.28%, predominantly observed in the East Asian subpopulation at a frequency of 1.9% including 2 homozygous occurrences. This frequency greatly exceeds the maximal expected allele frequency for a pathogenic variant in TTR (0.003%), suggesting this is a benign polymorphism found primarily in population(s) of East Asian origin. The variant of interest has not, to our knowledge, been reported in affected individuals via publications nor evaluated for functional impact by in vivo/vitro studies. One reputable clinical lab has classified the variant as "benign". Due to the synonymous nature of the variant along with the high allele frequency in the general population, this variant has been classified as Benign.
Invitae RCV000226050 SCV000284749 benign Amyloidogenic transthyretin amyloidosis 2017-12-27 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000036377 SCV000060030 benign not specified 2012-04-13 criteria provided, single submitter clinical testing Thr139Thr in exon 4 of TTR: This variant is not expected to have clinical signif icance because it does not alter an amino acid residue, is not located within th e splice consensus sequence, and it has been identified in 0.4% (9/2250) of chro mosomes from a broad, though clinically and racially unspecified population (dbS NP rs2276382).
Stanford Center for Inherited Cardiovascular Disease,Stanford University RCV000036377 SCV000280562 uncertain significance not specified 2014-06-12 no assertion criteria provided clinical testing Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. p.Thr139Thr (aka c.7349 G>A, c.417G>A, p.Thr119Thr). Given the type of variant and the presence in general population samples matching the patient's ancestry we consider this a variant of unknown significance, probably benign. This variant has not been reported in association with amyloidosis. It has been seen at low frequency in samples approximating the general population (see details below). Per their ClinVar submission, the Laboratory for Molecular Medicine classifies this variant as benign since it does not change the amino acid sequence, it is not located in the splice consensus sequence, and it is present as a rare variant in population samples (SCV000060030). This is a synonymous single nucleotide variant. It does not change the amino acid at this codon. Per the Athena report, five in silico splicing prediction algorithms predict the variant to create a new splice acceptor site. However, the original splice acceptor is unchanged so it is unclear what the impact would be on splicing. Essentially all TTR variants associated with amyloidosis are missense variants (see http://www.ibmc.up.pt/mjsaraiva/ttrmut.html, http://amyloidosismutations.com/attr.html, http://www.bumc.bu.edu/msr/ttr-database/ttr-mutations/). Considering the mechanism of disease in ATTR we would not expect either a synonymous variant or a null variant (via nonsense-mediated decay) to cause disease. It possible that a variant affecting could cause amyloidosis however this seems unlikely and to our knowledge it has not been reported. In total the variant has been seen in 10 of 7592 individuals from publicly available population datasets, with the highest frequency in patient's of Asian ancestry (which matches the patient's ancestry). It is listed in dbSNP (rs2276382) with submitted data from the following population datasets. The variant was reported online in 1 of 4300 Caucasian individuals and 0 of 2203 African-American individuals in the NHLBI Exome Sequencing Project dataset (as of June 12, 2014). The phenotype of that individual is not publicly available. The dataset is comprised of multiple cohorts, some of which were recruited from the general population, others were enriched for common cardiovascular disease. It was also observed in 9 of 1089 individuals in phase 1 of the 1000 genomes project including 5 of 197 Chinese individuals, 3 of 89 Japanese individuals, and 1 of 64 Mexican individuals. It looks like it has also been observed in the ClinSeq cohort, which is also a general population cohort.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.